Wall Street analyst estimates for Polyrizon Ltd. (PLRZ): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue.
Income Statement (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $1000 | $6000 | $5000 | $4000 | $118000 | $342000 |
| Gross Profit | -$1000 | -$6000 | -$5000 | -$4000 | -$118000 | -$342000 |
| Research & Development | $38000 | $245000 | $347000 | $332000 | $534000 | $2.1M |
| Selling, General & Admin | $33000 | $452000 | $548000 | $303000 | $768000 | $3.8M |
| Operating Expenses | $71000 | $697000 | $895000 | $635000 | $1.3M | $5.9M |
| Operating Income | -$72000 | -$703000 | -$895000 | -$635000 | -$1.3M | -$6.2M |
| EBITDA | -$72000 | -$703000 | -$772000 | -$631000 | -$1.4M | -$5.9M |
| Interest Expense | 0 | $2000 | $2000 | $2000 | $3000 | $3.1M |
| Pre-tax Income | -$73000 | -$711000 | -$779000 | -$600000 | -$1.5M | -$3.3M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$73000 | -$711000 | -$779000 | -$600000 | -$1.5M | -$3.3M |
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $-134.14 | $-2.07 |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $-134.14 | $-2.07 |
| Shares Outstanding (Diluted) | 0 | 0 | 0 | 0 | $11965 | $1.6M |
Price
| Price | $10.65 |
| Market Cap | $12M |
| Exchange | NASDAQ |
| Country | IL |
Related companies: AIM · CYCN · KTTA · NBY · PMCB · QNRX · RADX
Explore sector: Healthcare · Biotechnology
More sections of PLRZ: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks